Famotidine versus Ranitidine for the Short-Term Treatment of Duodenal Ulcer

Abstract

One-hundred and eighty-three patients with endoscopically proven duodenal ulcers, enrolled in this prospective, double-blind study, were randomly allocated to receive famotidine 40 mg once at night, 20 mg twice daily, 40 mg twice daily, or ranitidine 150 mg twice daily for 2 – 8 weeks. Pretreatment characteristics between the four groups were similar. After 4 weeks of treatment, among the famotidine-treated patients, 38 of 42 (90.5%) healed with the 40 mg once nightly regimen, 35 of 42 (83.3%) with 20 mg twice daily, and 37 of 41 (90.2%) with 40 mg twice daily. In the ranitidine group 40 of 43 patients (93.0%) healed. After 8 weeks of treatment, the respective data were: 97.6, 95.2, 100 and 93.0%. Different results between the famotidine groups and the ranitidine group were not statistically significant. All treatments were well tolerated and severe adverse events were rare. Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with ranitidine, indicating the importance of overnight gastric acidity in the pathogenesis of duodenal ulcer disease.

Anaphalactoid reaction to ranitidine in labour

“…As cimetidine and ranitidine are both used prophylactically in labour, it is important that obstetricians and anaesthetists are aware of this possibility so that appropriate measures can be taken if such a reaction occurs. It should also be noted that anaphalactoid reactions to ranitidine can occur after oral administration even in patients not previously exposed to the drug, as reported both in this case and in others 2,4 . The reactions usually take the form of stridor, dyspnoea, urticaria and facial and lingual oedema.…”

Inhibitory effect of famotidine on cat gastric secretion

“…On the ligth of all the above observations concerning our "in vivo" (present study) and "in vitro" [5] experimental data, and taking into account the excellent results obtained in preliminary clinical studies [17,22,23], from both a therapeutic and safety profile, famotidine must be considered a very good alternative to the available H2 antagonists in the treatment of peptic ulcer disease.…”

Standard-Dose Proton Pump Inhibitors in the Initial Non-eradication Treatment of Duodenal Ulcer: Systematic Review, Network Meta-Analysis, and Cost-Effectiveness Analysis

“…Figure 1 showed the selection process. Sixty-two RCTs (Barbara et al, 1985; Simon et al, 1985; Bardhan et al, 1986; Mccullough, 1986; Dobrilla et al, 1987; Marks and Wright, 1987; Alcalá-Santaella et al, 1989; Chelvam et al, 1989; Hui et al, 1989; Mulder et al, 1989; Graham et al, 1990; McFarland et al, 1990; Londong et al, 1991; Marks et al, 1991; Valenzuela et al, 1991; Delle Fave et al, 1992; Hotz et al, 1992; Kumar et al, 1992; Lysy et al, 1992; Wang et al, 1992, 2000, 2011, 2012; Ahmed et al, 1993; Tao and Yin, 1993; Hawkey et al, 1993; Misra et al, 1993; Zaterka et al, 1993; Judmaier and Koelz, 1994; Lanza et al, 1994; Li et al, 1994, 2001, 2010; Rensburg et al, 1994; Chang et al, 1995; Cremer et al, 1995; Ekström et al, 1995; Rehner et al, 1995; Schepp and Classen, 1995; Xiao, 1997; Cloud et al, 1998; Hallerback et al, 1998; Dekkers et al, 1999; Breiter et al, 2000; Meneghelli et al, 2000; Pei et al, 2000; Clinical Study Group of Pantoprazole in Shanghai, 2001; Hu, 2001; Tang and Hu, 2001; Xu, 2001, 2006; Gu, 2005; You et al, 2006; Ho et al, 2009; Huang, 2010; Liu and Cheng, 2011; Zou, 2012; Wang and Chen, 2013; Zhao et al, 2013; Liao, 2015; Chen, 2017; Chen et al, 2017) with 10,339 participants were included in the network meta-analysis (Li and Li, 2010). As shown in Supplementary Table S4, included trials were conducted in 27 countries or regions (e.g., Australia, Belgium, Brazil, Canada, China, France, Germany, Hong Kong, Iceland, India, Ireland, Israel, Italy, Karachi, Malaysia, Netherlands, Philippines, Poland, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, the United Kingdom, and the United States).…”